Recent studies showed that SGLT2i attenuate cardiac fibrosis in T2DM rodent models and TGF-β-induced fibroblast activation in human cardiac fibroblasts [63–65]. This evidence concerns the gene TGFB1 and type 2 diabetes mellitus.